In this keynote, Dan will draw on his experiences working at the legislative branch of Congress, the Centers for Medicare and Medicaid Services and various pharmaceutical companies to
discuss what changes industry and healthcare professionals could be in-store for after the power swing in Washington this past November.

With the growth of ACOs, CCOs, Patient-Centered Medical Homes, and Medical Neighborhoods changing the dynamic of how healthcare is delivered and supported by industry, this Keynote will provide listeners an inside look at how the current system may change.

---

With a transformation currently taking place in healthcare, new models of delivery have begun to unfold. Population Health Management occurs across the care continuum and can only be successful through equal collaboration from delivery systems, payers, and pharmaceutical companies.

This panel of industry leaders will discuss:

• Where stakeholders can work together to drive forward population health initiatives
• Changes needed that can better align efforts
• How the new system will manage, and pay, for medication over years to come

---

---

---

With the ACA changing the way healthcare is delivered in the US, and increased capability in fields such as genomics and network modeling, delivery of improved outcomes and meaningful benefit at the individual patient level are in reach. However, a change in philosophy is required for success, and a surrounding ecosystem support structure that can improve adherence, access and also provide the necessary tools and services to empower the patient will be just as imperative as the introduction of the drug itself.

This talk will discuss how Janssen is progressing on this journey towards providing, patients, caregivers and clinicians with a network of solutions that enhance overall outcomes associated with use of innovative new therapies.

---

This talk will focus on how increasingly, stakeholders across the care-continuum are realizing that the voice of the patient is the most valuable measurement that payers must consider when evaluating a medication.

With technology rapidly providing access to data never before available, this talk will explore:

• How do those responsible for patient care best leverage technology to capture and measure patient data in a way that is meaningful to evaluating how a drug is working?
• Strategies to successfully drive patient-centric data as provider and medication reimbursement becomes reliant upon the outcomes

---

---

This session will examine how a partnership was formed between Boehringer-Ingelheim and Humana, and the progress to date from the collaboration.

---

---

The implications of an increasingly cost-conscious healthcare system on science and R&D are simple: Medicines that provide an unmet need will be in high-demand, and those that provide incremental added value will have to have significant economic benefits over the current standard of care in order to gain reimbursement.

This panel will share perspectives from across the entire product development life-cycle from pre-clinical to post-approval in order to identify strategies that life-science companies can use to adapt their R&D efforts to meet these new demands for intelligent drug design.

---

---

---

Small Group Chats:
*Join two groups for 30 minute intervals

1) Defining a Patient Centric Strategy
Sachin Kamal-Bahl, VP & Head, Global Health & Value Innovation Center, PFIZER

2) Creating a Specialized Engagement Program for Integrated Care Systems
Susan Tappen, Senior Director, Managed Markets, SUNOVION

3) Risk-Shared Contracting Best Practices
Donna Forbes-White, Senior Director, Contracts & Compliance, CHIESI US

4) Social Media to Drive Patient Engagement
Greg Cohen, Senior Manager, Social Media & Influence, UCB

5) Nuts and Bolts of Developing a Beyond the Pill Program
Ken Bennett, Senior Director - Integrated Care & BGM, Diabetes PCU, SANOFI

6) Case-Study Follow-Up
Angeliki Cooney, Director, Thought Leadership, Strategic Planning, IMS HEALTH

---

---

---

---